MYCN and prostate carcinoma: These results indicate that IDCP may be involved in prostate cancer neuroendocrine differentiation, although the NE signature markers CHGA, SYP, NCAM1 (CD56), NKX2.1, MYCN, and AURKA were not elevated in the present case.